0.2824

0.46% 0.0013

After Hours: .28 -0.0024 -0.85%

IGC Pharma Inc (IGC)

Overview News Price History Option Chain Discussions Forecast Stock Split

IGC Pharma Inc stock is traded at $0.2824, with a volume of 681.54K. It is up +0.46% in the last 24 hours and down -7.29% over the past month. India Globalization Capital, Inc. engages in the development and commercialization of cannabis-based therapies to treat Alzheimer's, pain, nausea, eating disorders, several end points of Parkinson's, and epilepsy in humans, dogs, and cats. The company operates through two segments, Legacy Infrastructure and Medical Cannabis Based Alternative Therapies. The Legacy Infrastructure segment trades in infrastructure commodities, such as steel and iron ore; and rents heavy equipment. The Medical Cannabis Based Alternative Therapies segment offers IGC-501 for indications of neuropathic pain; Serosapse for indications of Parkinson's and other central nervous system disorders; Caesafin for seizures in cats and dogs; and Natrinol for indications of cancer and AIDS induced nausea and vomiting, as well as Hyalolex for Alzheimer's patients. The company was founded in 2005 and is based in Bethesda, Maryland.

Previous Close:

$0.2811

Open:

$0.2798

24h Volume:

681.54K

Relative Volume:

1.07

Market Cap:

$29.20M

Revenue:

$1.27M

Net Income/Loss:

$-7.12M

P/E Ratio:

-5.41

EPS:

-0.0522

Net Cash Flow:

$-5.28M

1W Performance:

-0.91%

1M Performance:

-7.29%

6M Performance:

+7.79%

1Y Performance:

-27.74%

1-Day Range:

$0.277

$0.29

1-Week Range:

$0.27

$0.29

52-Week Range:

$0.235

$0.4508

IGC Pharma Inc Stock (IGC) Company Profile

Name

IGC Pharma Inc

Sector

Healthcare (1067)

Industry

Biotechnology (595)

Phone

301-983-0998

Address

4336 Montgomery Avenue, Bethesda, MD

Employee

Twitter

@IGCIR

Next Earnings Date

2026-11-13

Latest SEC Filings

IGC's Discussions on Twitter

Compare IGC vs VRTX, REGN, MRNA, ARGX, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
IGC IGC Pharma Inc	0.2824	29.20M	1.27M	-7.12M	-5.28M	-0.0522
VRTX Vertex Pharmaceuticals Inc	526.19	133.37B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	788.04	81.13B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	198.88	79.40B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	959.49	60.03B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	204.97	43.93B	742.00K	-1.37B	-1.07B	-7.0731

IGC Pharma Inc Stock (IGC) Latest News

Sep 15, 2026

PullBack Stocks PDSB, PRSO, IGC, RETO: Who Breaks First? - openPR.com

Sep 15, 2026

Sep 14, 2026

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock. Raising P/T to $4.75." - ACCESS Newswire

Sep 14, 2026

Sep 12, 2026

IGC Pharma Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs

Sep 12, 2026

Sep 10, 2026

IGC Q1 2026 Earnings: Narrower-Than-Expected Loss as Clinical-Stage Pipeline Stays in FocusWeak Earnings Momentum - careplusvn.com

Sep 10, 2026

Sep 09, 2026

IGC Pharma Evaluates Recovery After Left Verdict - ACCESS Newswire

Sep 09, 2026

Sep 07, 2026

Price to earnings forward of IGC Pharma, Inc. – AMEX:IGC - TradingView

Sep 07, 2026

Sep 01, 2026

IGC Pharma (NYSE: IGC) Target Raised on Alzheimer's 2027 Outlook - marketscreener.com

Sep 01, 2026

Aug 31, 2026

IGC Pharma (IGC) Slips to $0.31 as Key Support Comes into FocusMerger Arbitrage - dars.gov.et

Aug 31, 2026

Aug 27, 2026

Nasdaq 30's VIVS, IGC, RIME, AIXI Stocks Now - openPR.com

Aug 27, 2026

Aug 26, 2026

Nasdaq 30’s VIVS, IGC, RIME, AIXI Stocks Now - FinancialContent

Aug 26, 2026

IGC Q1 2026 Earnings: Narrower Loss Beats Estimates as Pipeline Progress Supports SentimentMargin Improvement Report - careplusvn.com

Aug 26, 2026

Aug 24, 2026

IGC (IGC) Technicals: Falls 0.65% to $0.31 on the Day; Level Watch: $0.29 and $0.33 Define the Nearby Reference Levels in the Latest ReadingLarge Cap Trends - vinanet.vn

Aug 24, 2026

Aug 20, 2026

MicroCaps IGC, BIVI, ORBS, RIME Sub-$1 Stocks to Watch Now - openPR.com

Aug 20, 2026

Aug 18, 2026

IGC Pharma earnings matched, revenue fell short of estimates By Investing.com - Investing.com India

Aug 18, 2026

IGC (IGC) Earnings Data Review: The Bottom-Line Figure Outpaces Its Comparison at the Close; Session Reaction: Shares Move 1.43% Higher in the Current UpdatePost-Earnings Reaction - vinanet.vn

Aug 18, 2026

IGC Pharma earnings matched, revenue fell short of estimates - Investing.com

Aug 18, 2026

Aug 17, 2026

IGC Pharma Releases Q2 2026 Financial Results - AlphaStreet

Aug 17, 2026

VivoSim Labs (NASDAQ: VIVS) Among IGC, OSRH, IVF as FDA-Backed Human-Based Testing Gains Momentum - openPR.com

Aug 17, 2026

IGC Pharma execs buy 4.27M shares to settle $1.15M debt - scanx.trade

Aug 17, 2026

IGC Pharma Q2 Results: Sales up 39% YoY, EPS loss widens to $(0.03) - scanx.trade

Aug 17, 2026

IGC Looks 24.1% Overvalued on GF Value™ - GuruFocus

Aug 17, 2026

IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer's Trial Moves Within Six Randomizations of Enrollment Closure - Finviz

Aug 17, 2026

IGC Pharma Q2 Results: CALMA Nears Enrollment Closure - accessnewswire.com

Aug 17, 2026

Aug 14, 2026

IGC Pharma, Inc. 2026: Revenue $265K, EPS ($0.03) — 10-Q Summary - TradingView

Aug 14, 2026

IGC Pharma (NYSE: IGC) widens loss while Phase 2 Alzheimer’s trial hits key milestone - Stock Titan

Aug 14, 2026

IGC Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com

Aug 14, 2026

Microcaps TOON, IGC, SURG, MDXH to Watch Now as Earnings, AI and Biotech Catalysts Build - openPR.com

Aug 14, 2026

Aug 13, 2026

IGC Pharma (NYSE American:IGC): What Does the Latest Update Mean for Clinical Development? - Kalkine Media

Aug 13, 2026